Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38

US11939395B2 · kind B2 · utility

Assignee

• MORPHOSYS AG · DE

Inventors

• Michael Tesar · Heidelberg, DE
• Ute Jäger · Höchst im Odenwald, DE

Key dates

• Filing date: Jun 9, 2021
• Grant date: Mar 26, 2024
• Expiry date: Feb 13, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.